Levi Garraway, Roche's chief medical officer and head of global product development. Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback